Joseph Gilliam

“And again, thanks for having us as a part of the conference this year. So as it relates to Epioxa and our payer progress, I'd say, generally speaking, it's gone much better than what we had expected internally.”

“I think that was actually more like a six-part question and I'll work through it. But I get the heart of it really is an update of kind of where we stand today on the FDOXA launch and as we move forward here.”

“So, Joe or Tom, have you seen or are you seeing any sort of inflection or acceleration in Noridian, you know, again, with reimbursement in a solid place? and then is it fair to view neridian maybe as sort of an analog for when the rest of the max come up to speed thanks yeah tom i think clearly neridian is the the…”

“We've had a stronger-than-expected start to the year, and we're pleased to raise the full-year guidance so soon after setting it. There are a few key points worth highlighting.”

“I'll start off and Alex will add some color if he can. Maybe first I'll start from a macro perspective on the guidance itself. I mean, obviously, we were pleased to see the business continue to deliver and the momentum as we exited 2023, we’re entering 2024.”